Hormone Receptor Regulation of RNA Polymerase III
RNA 聚合酶 III 的激素受体调节
基本信息
- 批准号:10662332
- 负责人:
- 金额:$ 36.49万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-08-01 至 2026-06-30
- 项目状态:未结题
- 来源:
- 关键词:AgingAgonistAndrogensBindingBiologyBreast Cancer CellBreast Cancer cell lineCell Differentiation processCell ProliferationCell SurvivalCell physiologyCellsChIP-seqChromatinCodeCodon NucleotidesComplexDNADNA BindingDNA SequenceDataDevelopmentDiseaseElectron Transport Complex IIIEstradiolEstrogen Receptor alphaEstrogen Receptor betaEstrogen ReceptorsEstrogen receptor positiveEstrogensFRAP1 geneFamilyFeedbackFemaleGene Expression RegulationGenesGenetic TranscriptionGlucocorticoid ReceptorGlucocorticoidsGoalsHormone ReceptorHormonesHumanKnowledgeLigandsLinkLongevityMalignant NeoplasmsMammalian CellMeasuresMedicineMessenger RNAMetabolic DiseasesMolecularMutagenesisNormal CellNormal tissue morphologyNuclear Receptor GeneNuclear ReceptorsOncogenicOrganismPathway interactionsPermeabilityPharmaceutical PreparationsPharmacologic SubstancePhenotypePlayPolymerasePost-Transcriptional RegulationProgesteroneProgesterone ReceptorsProtein BiosynthesisProteinsProteomeRNA Polymerase IIRNA Polymerase IIIRegulationRepressionReproductionRibosomal RNARoleSignal TransductionSiteSmall RNASteroid ReceptorsTestingTissuesTranscription Factor TFIIIBTranscription Initiation SiteTranscription RepressorTransfer RNATranslationsTretinoinTumor Suppressor ProteinsUntranslated RNAVertebratesWorkantagonistcancer therapycell growthcofactordetection of nutrientdisorder controlgenetic testinggenome-wide analysishormonal signalshormone regulationinducible gene expressionknock-downlipophilicitymRNA Translationmanufacturemembermutantneoplasticnovelpromoterreceptor bindingrecruitretinoic acid receptor alpharibosome profilingsmall moleculestem cellsstemnesssteroid hormonetissue stem cellstranscription factortranscriptometranslational impacttranslatometransmission processtumortumor progressiontumorigenesis
项目摘要
Project summary
Steroid receptors are a subset of nuclear receptor (NR) transcription factors that are found only in vertebrates
and regulate essential functions such as organismal development and reproduction, while also impacting aging,
tumorigenesis, and cancer progression. Small lipophilic hormones bind to steroid receptors for estrogens (ER-
alpha and ER-beta), progesterone (PR), glucocorticoids (GR), and androgens (AR) and transmit their signal
through gene regulation. Since these small molecules can be synthetically modified and manufactured, a variety
of pharmaceutical drugs provide critical medicines for diseases including metabolic disorders, reproduction, and
cancer treatment. NR mechanism of action has been mostly studied at RNA polymerase II (Pol II) transcribed
genes including protein-coding mRNAs and small/long non-coding RNAs. Multiple NRs act in complexes on DNA
to activate or repress Pol II transcription. However, NR controlled cell transcriptomes are often not always tightly
correlated with the proteome due to post-transcriptional regulation that is not completely understood. We have
uncovered a second layer of coordinated NR activity through regulation of RNA Polymerase III (Pol III)
transcribed genes. Pol III transcribes small RNAs essential for translation of mRNAs into protein including tRNAs
and 5S rRNA and is a major node for controlling cell growth, stem cells, aging, and cancer. Negative regulation
of Pol III is commonly through the conserved repressor Maf1. Very little is known concerning how NRs regulate
Pol III in more complex mammalian cells and organisms. We discovered using genome-wide analyses of PR
chromatin binding in ER+PR+ breast cancer cell lines and tumors that PR localizes at multiple tRNA genes. PR
associates with the Pol III complex and decreases tRNA levels and protein synthesis. Progesterone recruits PR
and retinoic acid receptor alpha (RARα) to tRNA genes near a conserved DNA sequence resembling an NR
binding half site. Our hypothesis is that PR regulates Pol III transcription of tRNA genes through crosstalk with
RARα and recruitment of Maf1 resulting in decreased levels of target tRNA genes and selective translation. Aim
1 will determine how PR associates at tRNA genes, the role of RARα and other steroid receptors, and the NR
binding half site. Aim 2 will determine the role of Maf1 in PR modulation of Pol III transcription. Aim 3 will define
hormone-induced changes in the tRNA pool and the impact on translational efficiency. Regulation of Pol III is
vastly understudied compared to Pol II and crucial for normal and oncogenic cell phenotypes. Results of this
study will define a novel mechanism of NR action at Pol III genes that will help explain i) an additional layer of
hormone regulation that contributes to selective mRNA translation, and ii) how NRs converge on multiple cell
polymerases to impact cell growth, differentiation, stemness, and tumor progression.
项目摘要
类固醇受体是核受体(NR)转录因子的一个亚类,仅在脊椎动物中发现
并调节生物体发育和繁殖等基本功能,同时也影响衰老,
肿瘤发生和癌症进展。小的亲脂性激素与雌激素的类固醇受体(ER-1)结合。
α和ER-β)、孕酮(PR)、糖皮质激素(GR)和雄激素(AR)并传递它们的信号
通过基因调控。由于这些小分子可以合成修饰和制造,
的药物提供关键药物的疾病,包括代谢紊乱,生殖,
癌症治疗NR的作用机制主要是在RNA聚合酶II(Pol II)转录
基因包括蛋白质编码mRNA和小/长非编码RNA。多个NR以复合物形式作用于DNA
激活或抑制Pol II转录。然而,NR控制的细胞转录组通常并不总是紧密地结合在一起。
与蛋白质组相关,由于转录后调控,这是不完全理解的。我们有
通过RNA聚合酶III(Pol III)的调节,发现了第二层协调的NR活性
转录基因Pol III转录小RNA,这些小RNA对于mRNA翻译成包括tRNA在内的蛋白质至关重要
和5S rRNA,是控制细胞生长、干细胞、衰老和癌症的主要节点。负调控
Pol III的表达通常是通过保守的阻遏物Maf 1。关于核反应堆如何调节,
Pol III在更复杂的哺乳动物细胞和生物体中。我们通过对PR的全基因组分析发现,
ER+PR+乳腺癌细胞系和PR定位于多个tRNA基因的肿瘤中的染色质结合。PR
与Pol III复合物结合并降低tRNA水平和蛋白质合成。Progressive招聘PR
视黄酸受体α(RARα)与tRNA基因在类似NR的保守DNA序列附近
结合半位点。我们的假设是,PR通过与tRNA基因的串扰来调节Pol III转录。
RARα和Maf 1的募集导致靶tRNA基因水平降低和选择性翻译。目的
1将确定PR如何与tRNA基因相关,RARα和其他类固醇受体的作用,以及NR
结合半位点。目的二是确定Maf 1在PR调节Pol III转录中的作用。目标3将定义
酶诱导的tRNA库变化及其对翻译效率的影响。Pol III的调节是
与Pol II相比,其研究远远不足,并且对于正常和致癌细胞表型至关重要。成果
这项研究将定义NR在Pol III基因上作用的新机制,这将有助于解释i)
有助于选择性mRNA翻译激素调节,和ii)NR如何会聚于多个细胞
在一些实施方案中,本发明的组合物可通过使用聚合酶来影响细胞生长、分化、干性和肿瘤进展。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Peter Kabos其他文献
Peter Kabos的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Peter Kabos', 18)}}的其他基金
Cancer-associated fibroblasts in estrogen receptor positive breast cancer.
雌激素受体阳性乳腺癌中的癌症相关成纤维细胞。
- 批准号:
9903254 - 财政年份:2016
- 资助金额:
$ 36.49万 - 项目类别:
Cancer-associated fibroblasts in estrogen receptor positive breast cancer.
雌激素受体阳性乳腺癌中的癌症相关成纤维细胞。
- 批准号:
9082027 - 财政年份:2016
- 资助金额:
$ 36.49万 - 项目类别:
Regulation of anti-endocrine resistance of breast cancer by a network of non-codi
非codi网络对乳腺癌抗内分泌耐药性的调节
- 批准号:
8226638 - 财政年份:2012
- 资助金额:
$ 36.49万 - 项目类别:
Regulation of anti-endocrine resistance of breast cancer by a network of non-codi
非codi网络对乳腺癌抗内分泌耐药性的调节
- 批准号:
8699710 - 财政年份:2012
- 资助金额:
$ 36.49万 - 项目类别:
Regulation of anti-endocrine resistance of breast cancer by a network of non-codi
非codi网络对乳腺癌抗内分泌耐药性的调节
- 批准号:
8511589 - 财政年份:2012
- 资助金额:
$ 36.49万 - 项目类别:
Regulation of anti-endocrine resistance of breast cancer by a network of non-codi
非codi网络对乳腺癌抗内分泌耐药性的调节
- 批准号:
8913063 - 财政年份:2012
- 资助金额:
$ 36.49万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 36.49万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 36.49万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 36.49万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 36.49万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 36.49万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 36.49万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 36.49万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 36.49万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 36.49万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 36.49万 - 项目类别:
Grant-in-Aid for Scientific Research (C)